https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Approval-of-LinzessTablets-025-mg-in-Japan-for-Additional-Indication-of-Chronic-Constipation/default.aspx
https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Approval-of-LinzessTablets-025-mg-in-Japan-for-Additional-Indication-of-Chronic-Constipation/default.aspx